ArticleAlimentary pharmacology & therapeutics2022

Letter: potential selection bias in the real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease.

Motohiko Adomi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.